Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252499 · ClinicalTrials.gov registry record · NA
Insulin Resistance in Non-alcoholic Fatty Liver Disease
A NA study, sponsored by US Department of Veterans Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00252499: Clinical Trial NA study, sponsored by US Department of Veterans Affairs.
NCT00252499 is a NA study that was terminated before completion, run by US Department of Veterans Affairs. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252499, a NA study, was terminated before completion, sponsored by US Department of Veterans Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.
Primary Outcome
Liver fat was estimated by non-contrast CT scan measuring the density ratio between the liver and spleen by Hounsfield units (liver/spleen ratio), which has been previously correlated with liver fat quantification by magnetic resonance spectroscopy.Ten separate measurements equally distributed throughout the liver and spleen were obtained and the Hounsfield units averaged. In subjects with more than one slice through the liver and spleen, the values for all slices were averaged.
Interventions
- DRUG rosiglitazone
- DRUG fenofibrate
- DRUG placebo for rosiglitazone
- DRUG placebo for fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-08 |
| Phase | NA |
Why NCT00252499 stopped before completion
NCT00252499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which rosiglitazone is the first listed.
NCT00252499 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00252499 about?
NCT00252499 is a clinical study titled "Insulin Resistance in Non-alcoholic Fatty Liver Disease". The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining associations between hepatic and peripheral i...
What is the current status of trial NCT00252499?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2005-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00252499?
The interventions under investigation include: rosiglitazone (DRUG), fenofibrate (DRUG), placebo for rosiglitazone (DRUG), placebo for fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00252499?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00252499's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia